<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567278</url>
  </required_header>
  <id_info>
    <org_study_id>2009-01</org_study_id>
    <secondary_id>DE/CA84/73-KL-30-09</secondary_id>
    <nct_id>NCT03567278</nct_id>
  </id_info>
  <brief_title>Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis (2009-01)</brief_title>
  <acronym>TA-FIM</acronym>
  <official_title>Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility Trial on the ACURATE TA™ transapical implantation in patients presenting severe
      symptomatic aortic stenosis to collect human feasibility data pertaining to the safety and
      performance of the device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm, prospective, multicenter, open trial up to 5 year follow-up with the SYMETIS
      ACURATE TA™ which is an aortic bioprosthesis for minimal invasive implantation via
      transapical access to treat patients with severe symptomatic aortic stenosis where
      conventional aortic valve replacement (AVR) via open heart surgery is considered to be
      associated with high surgical risk for evaluating the feasibility and performance of the
      implantation and the safety at 30-Day follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Medical Device Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of Major Adverse Valve-Related Events (MAVRE) related to ACURATE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance endpoint</measure>
    <time_frame>Up to 24-hours post-procedure</time_frame>
    <description>Stable ACURATE placement at intended site as assessed by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance endpoint</measure>
    <time_frame>Up to 24-hours post-procedure</time_frame>
    <description>Adequate ACURATE device function as assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days, 60 days, 3 months, 6 months and 12 months</time_frame>
    <description>Freedom from Death at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAVRE at follow-up</measure>
    <time_frame>discharge or 7 days, 3 months, 6 months and 12 months</time_frame>
    <description>Rate of MAVRE at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE or Major Adverse Cardiac and Cerebrovascular Event</measure>
    <time_frame>1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Rate of MACCE at follow up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <arm_group>
    <arm_group_label>ACURATE TA™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with ACURATE TA™ Bioprosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE TA™</intervention_name>
    <description>ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.</description>
    <arm_group_label>ACURATE TA™</arm_group_label>
    <other_name>ACURATE TA™ Transapical Aortic Bioprosthesis and Delivery System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 75 years;

          -  Additive EuroSCORE &gt; 9 and/or STS &gt; 9%;

          -  Severe symptomatic AS assessed by echocardiography, documented by a derived mean
             gradient &gt; 40mmHg,and a native Aortic Valve Area (AVA) &lt; 0.8 cm² or Aortic Valve Area
             Index (AVAI) &lt; 0.6 cm²/m²;

          -  NYHA Functional Class &gt; II;

          -  Aortic annulus (AAn) diameters between and including 21 mm up to 27 mm (21mm ≤ AAn
             ≤27mm) by transoesophageal echocardiography;

          -  Sinotubular junction (STJ) higher than 1,1times the native aortic annulus diameter
             (AAn) [STJ&gt;1.1xAAn] AND STJ&lt;45mm by transoesophageal echocardiography;

          -  Patient understands the implications of participating in the study and provides signed
             informed consent

        Exclusion Criteria:

          -  Congenital unicuspid or bicuspid aortic valve;

          -  Severe eccentricity of calcification;

          -  Severe mitral regurgitation (&gt; 2°);

          -  Pre-existing prosthetic heart valve in any position and /or prosthetic ring;

          -  Severe transapical access problem, non-reachable LV apex;

          -  Previous surgery of the LV using a patch, such as the Dor procedure;

          -  Presence of apical LV thrombus;

          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation;

          -  Acute Myocardial Infarction (AMI) within 1 month prior to the procedure;

          -  PCI within 1 month prior to the procedure;

          -  Previous Transient Ischemic Accident (TIA) or stroke in the last 3 months;

          -  Untreated clinically significant CAD requiring revascularization;

          -  Hemodynamic instability: systolic pressure &lt;90mmHg without afterload reduction, shock,
             need for inotropic support or intra-aortic balloon pump;

          -  Severe left ventricular dysfunction with a LV Ejection Fraction (LVEF) &lt; 25% by
             echocardiography;

          -  Calcified pericardium;

          -  Septal hypertrophy;

          -  Primary Hypertrophic Obstructive Cardiomyopathy (HOCM);

          -  Active infection, endocarditis or pyrexia;

          -  Active peptic ulcer or Gastrointestinal (GI) bleeding within the past 3 months;

          -  Significant hepatic involvement (Child &gt; B);

          -  Major lung disease (FEV &lt; 0.8 or FEV1% &lt; 30% of normal);

          -  Pulmonary hypertension;

          -  History of bleeding diathesis or coagulopathy;

          -  Hematologic disorder (WBC&lt;3000mm3, Hb&lt;9g/dL, platelet count &lt;50000 cells/ mm3);

          -  Serum creatinine level greater than 3.0 mg/dL or chronic renal failure requiring
             dialysis;

          -  Neurological disease severely affecting ambulation or daily functioning, including
             dementia;

          -  Other procedure scheduled at the same time, whether surgery or percutaneous approach;

          -  Emergency procedure;

          -  Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions;

          -  Known hypersensitivity/contraindication to any study medication, contrast media, or
             nitinol;

          -  Currently participating in an investigational drug or another device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Mohr, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Westdeutsches Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Herz- und Gefäßchirurgie</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik für Herz-und Gefäßchirurgie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 15, 2018</last_update_submitted>
  <last_update_submitted_qc>June 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Symptomatic Aortic Valve Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

